Developer docs
API playgroundTry for free, no card

Search company profiles

Scenic Biotech

Full company profile

uuid00008dd

Namestring
Scenic Biotech
Legal namestring
Scenic Biotech B.V.
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Scenic Biotech B.V. is a privately held Dutch biotech founded in 2017 in Amsterdam that develops disease-modifying therapies for rare neuro- and metabolic genetic disorders through a proprietary approach called modifier therapy. Rather than targeting the primary disease-causing mutation, the company identifies and acts on compensatory "modifier genes" that can neutralize or bypass disease impact. The core technology is Cell-Seq™, a functional genomics platform that uses haploid human cells and gene-trap mutagenesis to systematically screen for modifier genes, generate high-resolution disease maps, and validate novel drug targets. Scenic has built a proprietary data warehouse of modifier genes across more than a dozen diseases and has published extensively in Nature and Science between 2015 and 2025.

The company's pipeline includes wholly owned small-molecule and antisense oligonucleotide programs. The lead asset, SC6177, is a brain-penetrant PLA2G15 inhibitor in IND-enabling studies for Batten Disease, Niemann Pick Type C, Frontotemporal Lobar Degeneration, and (as of 2026) Parkinson's disease via the Michael J. Fox Foundation LITE program; first-in-human trials are targeted for 2027. Additional programs include a Galactokinase (GalK) inhibitor for Galactosemia and an ABHD18 mitochondrial modifier (ASO modality) for Barth Syndrome and cardiomyopathy. Multiple undisclosed neurometabolic programs target indications including X-ALD, HSAN1, and MacTel2.

Scenic operates a dual business model: in-house therapeutic development for long-term clinical and commercial value, and Cell-Seq platform licensing to major pharmaceutical partners (Genentech since 2020, Bristol Myers Squibb since 2024 with two expansions, Alnylam since 2025, and Ono Pharmaceutical since 2026) for upfront payments, research funding, and milestone-based revenue. The company is venture-backed (Eir Ventures, BioMedPartners, Vesalius Biocapital, Inkef, BioGeneration Ventures, Oxford Science Enterprises) with a $31M Series A closed in March 2022 and currently operates with 11–50 employees across Amsterdam headquarters and a New York office.

Short descriptiontext

Scenic Biotech is a Dutch development-stage biotech that uses its proprietary Cell-Seq haploid-cell functional genomics platform to identify modifier genes and develop first-in-class small-molecule and ASO therapies for rare neuro- and metabolic genetic diseases, licensing the platform to major pharmaceutical partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAmsterdam, Netherlands
HQ citystring
Amsterdam
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
functional genomics platform, modifier gene discovery, rare disease therapeutics, small molecule inhibitors, drug discovery services
Industry3 codes
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Rare Disease Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Platform Licensing & Collaborations
TypeLicensing Royalties
Description

Scenic Biotech licenses its Cell-Seq platform to major pharmaceutical companies (Genentech, Bristol Myers Squibb, Alnylam, Ono Pharmaceutical) for target discovery, pathway elucidation, and indication expansion. Revenue is generated through upfront payments, research funding, and milestone payments contingent on achievement of research, development, and commercial milestones.

scenicbiotech.com
2In-house Therapeutic Development
TypeLicensing Royalties
Description

Scenic develops wholly owned small molecule inhibitor programs (PLA2G15, GalK, ABHD18, and undisclosed targets) targeting neuro- and metabolic diseases. Revenue would be generated through clinical development and eventual commercialization, or through out-licensing of therapeutic assets to pharma partners.

scenicbiotech.com
3Series A Funding
TypeLicensing Royalties
Description

The company raised $31 million in Series A funding in March 2022, led by Eir Ventures, BioMedPartners, and Vesalius Biocapital, to support its transition into a development-stage biotech and advance its pipeline and collaborations.

scenicbiotech.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Scenic Biotech develops disease-modifying therapies for rare neuro- and metabolic diseases using its proprietary Cell-Seq™ functional genomics platform, which systematically identifies modifier genes—compensatory genes that counteract disease-causing mutations—via haploid human cell screening and gene-trap mutagenesis. The company licenses this platform to major pharmaceutical companies (Genentech, Bristol Myers Squibb, Alnylam, Ono Pharmaceutical) for target discovery while independently developing a pipeline of first-in-class small molecule and ASO therapeutics, including lead candidate SC6177 (a brain-penetrant PLA2G15 inhibitor for neurodegenerative lysosomal diseases).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • PLA2G15 inhibition significantly improves disease course in NPC mouse models, with improved neurodegeneration, reduced spleen and liver damage, improved neurological symptoms, and increased survival
+2 more records
Product overview1 text field

Scenic Biotech is a neurometabolic company developing disease-modifying therapies based on its proprietary Cell-Seq functional genomics platform. The company's core offering centers on modifier therapy—a radically new approach that acts on compensatory genes to neutralize disease impact rather than targeting primary mutations. The Cell-Seq platform uses haploid human cells and gene-trap mutagenesis to map disease pathways and identify novel drug targets. The lead product, SC6177, is a brain-penetrant small molecule inhibitor targeting PLA2G15 for lysosomal restoration across neurodegenerative diseases. Additional pipeline programs include Galactokinase (GalK) inhibitors for Galactosemia, ABHD18 mitochondrial modifiers for cardiomyopathy, and multiple undisclosed neurometabolic targets. The company operates a fully owned pipeline complemented by strategic collaborations with Genentech, Bristol Myers Squibb, Alnylam, and Ono Pharmaceutical.

Product and service5 records
1Cell-Seq™ Functional Genomics Platform
CategoryFunctional Genomics Platform / Drug Discovery Technology
Description

A proprietary functional genomics discovery platform that uses haploid human cells (carrying only a single copy of every gene) and gene-trap mutagenesis to systematically identify modifier genes—compensatory genes that counteract the effect of disease-causing genes. The platform uses fluorescent labeling, FACS isolation, and DNA sequencing to generate high-resolution disease maps. It is licensed to pharmaceutical companies (Genentech, Bristol Myers Squibb, Alnylam, Ono Pharmaceutical) for target discovery, pathway elucidation, and indication expansion.

2SC6177 (PLA2G15 Inhibitor Program)
CategorySmall Molecule Therapeutics — Neurodegenerative Disease
Description

A brain-penetrant small molecule inhibitor targeting PLA2G15, a lysosomal phospholipase A2 that degrades BMP (bis(monoacylglycero)phosphate), a lipid central to lysosomal function. Designed to elevate endogenous BMP levels and restore lysosomal function in neurodegenerative diseases. Being developed for Batten Disease, Niemann Pick Type C (NPC), Frontotemporal Lobar Degeneration (FTLD), and Parkinson's disease. In IND-enabling studies with first-in-human trials targeted for 2027.

3Galactokinase (GalK) Inhibitor Program
CategorySmall Molecule Therapeutics — Metabolic Disease
Description

A small-molecule allosteric covalent inhibitor program targeting Galactokinase (GalK) for the treatment of Galactosemia, a rare inherited disorder of carbohydrate metabolism that causes neurological and psychiatric deficits. Preclinical studies currently being initiated.

4ABHD18 Mitochondrial Modifier Program
CategoryOligonucleotide Therapeutics — Mitochondrial / Cardiac Disease
Description

An antisense oligonucleotide (ASO) program targeting ABHD18, a novel therapeutic target identified through Cell-Seq as a key regulator of cardiolipin biosynthesis and mitochondrial integrity. ABHD18 loss was shown to overcome severe disease characteristics caused by BTHS-associated TAZ gene, achieving full suppression of all Barth Syndrome disease hallmarks in preclinical models. Published in Nature 2025.

5Undisclosed Neurometabolic Target Programs
CategoryTherapeutic Pipeline — Neurometabolic Diseases
Description

Multiple genetically validated undisclosed therapeutic targets for neurometabolic diseases, including programs targeting X-linked adrenoleukodystrophy (X-ALD, affecting the nervous system and adrenal glands), HSAN1 (inherited peripheral neuropathy), and MacTel2 (macular telangiectasia type 2, an eye disease affecting the macula).

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-11
Description

Scenic Biotech joined the Michael J. Fox Foundation's LRRK2 Investigative Therapeutics Exchange (LITE) program to evaluate its first-in-class PLA2G15 inhibitor program as a disease-modifying approach for Parkinson's disease, including patients with LRRK2 mutations. The collaboration leverages LITE's LRRK2 biology expertise, biomarker infrastructure, and validated preclinical models developed at the University of Dundee to generate translational data supporting future clinical development. PLA2G15 inhibitors are designed to elevate endogenous BMP levels and restore lysosomal function, addressing a core driver of neurodegeneration linked to impaired glucocerebrosidase activity in genetic forms of Parkinson's disease.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2026-06-11
Description

University of Dundee, through the MJFF LITE program, provides validated preclinical models and biomarker expertise to test Scenic's PLA2G15 inhibitors in the context of LRRK2-linked Parkinson's disease. Dario Alessi, PhD, Director of the MRC Protein Phosphorylation Unit, serves as LITE Principal Investigator.

3Bristol Myers Squibb
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-26
Description

Scenic further expanded its platform collaboration with Bristol Myers Squibb, reaching a milestone and expanding the scope to identify novel target biology. The partnership leverages Scenic's Cell-Seq platform to unlock underlying genetic interactions of cellular pathways for undisclosed Bristol Myers Squibb targets, facilitating indication selection and expansion and accelerating drug development.

scenicbiotech.com
4Ono Pharmaceutical
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-07
Description

Scenic entered a license and research agreement with Ono Pharmaceutical to utilize Scenic's Cell-Seq platform for the discovery of novel therapeutic targets. This marks Scenic's fourth Cell-Seq collaboration with a major pharmaceutical company, joining ongoing multi-year agreements with Genentech, Bristol Myers Squibb, and Alnylam.

scenicbiotech.com
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2025-09-03
Description

Scenic collaborated with Dr. Jason Moffat's team at The Hospital for Sick Children (SickKids) in Toronto on a study identifying ABHD18 as a modifier gene for Barth Syndrome. The study was published in Nature 2025 and identified ABHD18 as a novel therapeutic target, with deactivation of ABHD18 found to rescue mitochondrial defects and achieve full suppression of Barth Syndrome disease hallmarks in preclinical models.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-08-26
Description

Scenic entered a license and research agreement with Alnylam Pharmaceuticals to leverage its Cell-Seq platform for discovering novel targets for RNAi therapeutics. This collaboration marks Scenic's third Cell-Seq collaboration with major US biotech and pharmaceutical companies, following ongoing multi-year agreements with Genentech and Bristol Myers Squibb. The collaboration harnesses Cell-Seq's capacity to deliver genetic insights that drive novel therapeutic discovery and development.

7Bristol Myers Squibb (Extended Collaboration)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-06-12
Description

Scenic extended its research collaboration with Bristol Myers Squibb for the second time, working to identify target biology for indication selection and expansion. The growth of this partnership highlights the unique power of the Cell-Seq platform to unlock underlying genetic interactions of cellular pathways for novel drug targets.

scenicbiotech.com
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2025-05-07
Description

Scenic collaborated with Dr. Monther Abu-Remaileh's team at Stanford University on the discovery and validation of PLA2G15 as a drug target for neuro- and metabolic diseases. The research was published in Nature 2025 and demonstrated that inhibiting PLA2G15 can significantly improve disease course in NPC mouse models, with relevance to Batten Disease, Niemann Pick Type C, and Frontotemporal Lobar Degeneration.

9Bristol Myers Squibb (Initial Collaboration)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-04-30
Description

Scenic entered a research collaboration with Bristol Myers Squibb to accelerate the development of Bristol Myers Squibb's drug targets by identifying target biology for indication selection and expansion. Scenic received an upfront payment and potential additional payments contingent upon achievement of research, development, and commercial milestones.

scenicbiotech.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-01-01
Description

Scenic Biotech collaborated with Genentech to discover modifier genes to tackle complex diseases. Scenic utilizes its Cell-Seq platform to identify drug targets in multiple therapeutic areas of Genentech's interest. This multi-year partnership highlights mutual commitment to innovation and belief in the transformative potential of genetic research. Announced as Scenic's first major pharma collaboration.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pioneer in modifier-gene-driven drug discovery, also founded by Charles Homcy and using functional genomics to identify compensatory genes in genetic disease. Closest conceptual comparator to Scenic's modifier-therapy thesis.

TypeBroad incumbent
Description

AI/ML-enabled drug discovery platform using high-throughput biology for novel target identification. Competes with Cell-Seq in supplying pharma partners with functional-genomics-derived targets, though at a much larger scale.

TypeDirect peer
Description

Focused on neurodegeneration and lysosomal biology, with a lead program (tividenofusp alfa) for CLN2/Batten Disease. Directly competes with Scenic's PLA2G15 program in lysosomal indications and shares brain-penetrant therapeutic modality.

TypeBroad incumbent
Description

Genetic-disease-focused biotech with multiple rare-disease programs including in cardiology and metabolism. Comparable as a rare-disease therapeutics platform that licenses and develops genetically validated targets.

TypeBroad incumbent
Description

Established rare-disease biotech with marketed therapies in Batten Disease (Brineura) and other lysosomal disorders. Direct overlap with Scenic's PLA2G15 indications and represents both competitor and potential out-licensing partner.

TypeEmerging player
Description

Rare-endocrine-disease biotech with approved therapy (Palsonify). Comparable as a development-stage rare-disease company using genetic/biological insights to develop small-molecule therapies with pharma-partnered economics.

TypeEmerging player
Description

ML-enabled functional-genomics platform identifying novel targets through induced pluripotent stem cells. Competes with Cell-Seq in supplying pharma partners with genetically validated targets, with a partnership model overlapping with Scenic's.

TypeEmerging player
Description

Genetic-medicine company using genomics-derived insights to develop cardiovascular therapies, with pharma partnerships (e.g., Lilly). Comparable as a platform company monetizing genetic insights through partnerships and in-house pipeline.

9Haplogen Genomics
TypeOthers
Description

Co-founded by Scenic co-founder Sebastian Nijman; uses haploid genetic screens for target discovery. Closely related platform technology peer founded on the same scientific foundation as Cell-Seq.

TypeRegional player
Description

European clinical-stage biotech focused on microbiome-related therapies for severe diseases. Comparable as a European rare-disease biotech in similar development stage and partnership model, though different therapeutic modality.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Scenic Biotech

Rare Disease Therapeuticsscenicbiotech.com

Scenic Biotech is a Dutch development-stage biotech that uses its proprietary Cell-Seq haploid-cell functional genomics platform to identify modifier genes and develop first-in-class small-molecule and ASO therapies for rare neuro- and metabolic genetic diseases, licensing the platform to major pharmaceutical partners.

What Scenic Biotech does

Scenic Biotech B.V. is a privately held Dutch biotech founded in 2017 in Amsterdam that develops disease-modifying therapies for rare neuro- and metabolic genetic disorders through a proprietary approach called modifier therapy. Rather than targeting the primary disease-causing mutation, the company identifies and acts on compensatory "modifier genes" that can neutralize or bypass disease impact. The core technology is Cell-Seq™, a functional genomics platform that uses haploid human cells and gene-trap mutagenesis to systematically screen for modifier genes, generate high-resolution disease maps, and validate novel drug targets. Scenic has built a proprietary data warehouse of modifier genes across more than a dozen diseases and has published extensively in Nature and Science between 2015 and 2025.

The company's pipeline includes wholly owned small-molecule and antisense oligonucleotide programs. The lead asset, SC6177, is a brain-penetrant PLA2G15 inhibitor in IND-enabling studies for Batten Disease, Niemann Pick Type C, Frontotemporal Lobar Degeneration, and (as of 2026) Parkinson's disease via the Michael J. Fox Foundation LITE program; first-in-human trials are targeted for 2027. Additional programs include a Galactokinase (GalK) inhibitor for Galactosemia and an ABHD18 mitochondrial modifier (ASO modality) for Barth Syndrome and cardiomyopathy. Multiple undisclosed neurometabolic programs target indications including X-ALD, HSAN1, and MacTel2.

Scenic operates a dual business model: in-house therapeutic development for long-term clinical and commercial value, and Cell-Seq platform licensing to major pharmaceutical partners (Genentech since 2020, Bristol Myers Squibb since 2024 with two expansions, Alnylam since 2025, and Ono Pharmaceutical since 2026) for upfront payments, research funding, and milestone-based revenue. The company is venture-backed (Eir Ventures, BioMedPartners, Vesalius Biocapital, Inkef, BioGeneration Ventures, Oxford Science Enterprises) with a $31M Series A closed in March 2022 and currently operates with 11–50 employees across Amsterdam headquarters and a New York office.

Scenic Biotech firmographics

Firmographics
Name
Scenic Biotech
Legal name
Scenic Biotech B.V.
Website
https://scenicbiotech.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Scenic Biotech is a Dutch development-stage biotech that uses its proprietary Cell-Seq haploid-cell functional genomics platform to identify modifier genes and develop first-in-class small-molecule and ASO therapies for rare neuro- and metabolic genetic diseases, licensing the platform to major pharmaceutical partners.
Ownership category
akta.pro rank

Scenic Biotech industry classification

Industry
Product category
Rare Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Functional genomics platform
  • Modifier gene discovery
  • Rare disease therapeutics
  • Small molecule inhibitors
  • Drug discovery services

Where Scenic Biotech is headquartered

Location

Headquarters

HQ city
Amsterdam
HQ country
Netherlands
HQ region
Europe

Offices2 records

Markets served

Scenic Biotech business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Platform Licensing & Collaborations: Scenic Biotech licenses its Cell-Seq platform to major pharmaceutical companies (Genentech, Bristol Myers Squibb, Alnylam, Ono Pharmaceutical) for target discovery, pathway elucidation, and indication expansion. Revenue is generated through upfront payments, research funding, and milestone payments contingent on achievement of research, development, and commercial milestones.
  2. In-house Therapeutic Development: Scenic develops wholly owned small molecule inhibitor programs (PLA2G15, GalK, ABHD18, and undisclosed targets) targeting neuro- and metabolic diseases. Revenue would be generated through clinical development and eventual commercialization, or through out-licensing of therapeutic assets to pharma partners.
  3. Series A Funding: The company raised $31 million in Series A funding in March 2022, led by Eir Ventures, BioMedPartners, and Vesalius Biocapital, to support its transition into a development-stage biotech and advance its pipeline and collaborations.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Scenic Biotech product offering

Product offering

Core offering

Scenic Biotech develops disease-modifying therapies for rare neuro- and metabolic diseases using its proprietary Cell-Seq™ functional genomics platform, which systematically identifies modifier genes—compensatory genes that counteract disease-causing mutations—via haploid human cell screening and gene-trap mutagenesis. The company licenses this platform to major pharmaceutical companies (Genentech, Bristol Myers Squibb, Alnylam, Ono Pharmaceutical) for target discovery while independently developing a pipeline of first-in-class small molecule and ASO therapeutics, including lead candidate SC6177 (a brain-penetrant PLA2G15 inhibitor for neurodegenerative lysosomal diseases).

Product overview

Scenic Biotech is a neurometabolic company developing disease-modifying therapies based on its proprietary Cell-Seq functional genomics platform. The company's core offering centers on modifier therapy—a radically new approach that acts on compensatory genes to neutralize disease impact rather than targeting primary mutations. The Cell-Seq platform uses haploid human cells and gene-trap mutagenesis to map disease pathways and identify novel drug targets. The lead product, SC6177, is a brain-penetrant small molecule inhibitor targeting PLA2G15 for lysosomal restoration across neurodegenerative diseases. Additional pipeline programs include Galactokinase (GalK) inhibitors for Galactosemia, ABHD18 mitochondrial modifiers for cardiomyopathy, and multiple undisclosed neurometabolic targets. The company operates a fully owned pipeline complemented by strategic collaborations with Genentech, Bristol Myers Squibb, Alnylam, and Ono Pharmaceutical.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cell-Seq™ Functional Genomics Platform A proprietary functional genomics discovery platform that uses haploid human cells (carrying only a single copy of every gene) and gene-trap mutagenesis to systematically identify modifier genes—compensatory genes that counteract the effect of disease-causing genes. The platform uses fluorescent labeling, FACS isolation, and DNA sequencing to generate high-resolution disease maps. It is licensed to pharmaceutical companies (Genentech, Bristol Myers Squibb, Alnylam, Ono Pharmaceutical) for target discovery, pathway elucidation, and indication expansion.
  • SC6177 (PLA2G15 Inhibitor Program) A brain-penetrant small molecule inhibitor targeting PLA2G15, a lysosomal phospholipase A2 that degrades BMP (bis(monoacylglycero)phosphate), a lipid central to lysosomal function. Designed to elevate endogenous BMP levels and restore lysosomal function in neurodegenerative diseases. Being developed for Batten Disease, Niemann Pick Type C (NPC), Frontotemporal Lobar Degeneration (FTLD), and Parkinson's disease. In IND-enabling studies with first-in-human trials targeted for 2027.
  • Galactokinase (GalK) Inhibitor Program A small-molecule allosteric covalent inhibitor program targeting Galactokinase (GalK) for the treatment of Galactosemia, a rare inherited disorder of carbohydrate metabolism that causes neurological and psychiatric deficits. Preclinical studies currently being initiated.
  • ABHD18 Mitochondrial Modifier Program An antisense oligonucleotide (ASO) program targeting ABHD18, a novel therapeutic target identified through Cell-Seq as a key regulator of cardiolipin biosynthesis and mitochondrial integrity. ABHD18 loss was shown to overcome severe disease characteristics caused by BTHS-associated TAZ gene, achieving full suppression of all Barth Syndrome disease hallmarks in preclinical models. Published in Nature 2025.
  • Undisclosed Neurometabolic Target Programs Multiple genetically validated undisclosed therapeutic targets for neurometabolic diseases, including programs targeting X-linked adrenoleukodystrophy (X-ALD, affecting the nervous system and adrenal glands), HSAN1 (inherited peripheral neuropathy), and MacTel2 (macular telangiectasia type 2, an eye disease affecting the macula).

Quantifiable outcome

  • PLA2G15 inhibition significantly improves disease course in NPC mouse models, with improved neurodegeneration, reduced spleen and liver damage, improved neurological symptoms, and increased survival
  • +2 more outcomes

Companies that use Scenic Biotech

Customer profile

Segments2 records

Ideal customer profiles2 records

Scenic Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Scenic Biotech partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and supporting.

  • Michael J. Fox Foundation (MJFF)coreStrategic or Co-development Partner · 11 June 2026Scenic Biotech joined the Michael J. Fox Foundation's LRRK2 Investigative Therapeutics Exchange (LITE) program to evaluate its first-in-class PLA2G15 inhibitor program as a disease-modifying approach for Parkinson's disease, including patients with LRRK2 mutations. The collaboration leverages LITE's LRRK2 biology expertise, biomarker infrastructure, and validated preclinical models developed at the University of Dundee to generate translational data supporting future clinical development. PLA2G15 inhibitors are designed to elevate endogenous BMP levels and restore lysosomal function, addressing a core driver of neurodegeneration linked to impaired glucocerebrosidase activity in genetic forms of Parkinson's disease.
  • University of Dundee (MRC Protein Phosphorylation Unit)supportingStrategic or Co-development Partner · 11 June 2026University of Dundee, through the MJFF LITE program, provides validated preclinical models and biomarker expertise to test Scenic's PLA2G15 inhibitors in the context of LRRK2-linked Parkinson's disease. Dario Alessi, PhD, Director of the MRC Protein Phosphorylation Unit, serves as LITE Principal Investigator.
  • Bristol Myers SquibbcoreTechnology or Integration · 26 January 2026Scenic further expanded its platform collaboration with Bristol Myers Squibb, reaching a milestone and expanding the scope to identify novel target biology. The partnership leverages Scenic's Cell-Seq platform to unlock underlying genetic interactions of cellular pathways for undisclosed Bristol Myers Squibb targets, facilitating indication selection and expansion and accelerating drug development.
  • Ono PharmaceuticalcoreTechnology or Integration · 7 January 2026Scenic entered a license and research agreement with Ono Pharmaceutical to utilize Scenic's Cell-Seq platform for the discovery of novel therapeutic targets. This marks Scenic's fourth Cell-Seq collaboration with a major pharmaceutical company, joining ongoing multi-year agreements with Genentech, Bristol Myers Squibb, and Alnylam.
  • The Hospital for Sick Children (SickKids), TorontosupportingStrategic or Co-development Partner · 3 September 2025Scenic collaborated with Dr. Jason Moffat's team at The Hospital for Sick Children (SickKids) in Toronto on a study identifying ABHD18 as a modifier gene for Barth Syndrome. The study was published in Nature 2025 and identified ABHD18 as a novel therapeutic target, with deactivation of ABHD18 found to rescue mitochondrial defects and achieve full suppression of Barth Syndrome disease hallmarks in preclinical models.
  • Alnylam PharmaceuticalscoreTechnology or Integration · 26 August 2025Scenic entered a license and research agreement with Alnylam Pharmaceuticals to leverage its Cell-Seq platform for discovering novel targets for RNAi therapeutics. This collaboration marks Scenic's third Cell-Seq collaboration with major US biotech and pharmaceutical companies, following ongoing multi-year agreements with Genentech and Bristol Myers Squibb. The collaboration harnesses Cell-Seq's capacity to deliver genetic insights that drive novel therapeutic discovery and development.
  • Bristol Myers Squibb (Extended Collaboration)coreTechnology or Integration · 12 June 2025Scenic extended its research collaboration with Bristol Myers Squibb for the second time, working to identify target biology for indication selection and expansion. The growth of this partnership highlights the unique power of the Cell-Seq platform to unlock underlying genetic interactions of cellular pathways for novel drug targets.
  • Stanford University (Dr. Monther Abu-Remaileh Lab)supportingStrategic or Co-development Partner · 7 May 2025Scenic collaborated with Dr. Monther Abu-Remaileh's team at Stanford University on the discovery and validation of PLA2G15 as a drug target for neuro- and metabolic diseases. The research was published in Nature 2025 and demonstrated that inhibiting PLA2G15 can significantly improve disease course in NPC mouse models, with relevance to Batten Disease, Niemann Pick Type C, and Frontotemporal Lobar Degeneration.
  • Bristol Myers Squibb (Initial Collaboration)coreTechnology or Integration · 30 April 2024Scenic entered a research collaboration with Bristol Myers Squibb to accelerate the development of Bristol Myers Squibb's drug targets by identifying target biology for indication selection and expansion. Scenic received an upfront payment and potential additional payments contingent upon achievement of research, development, and commercial milestones.
  • GenentechcoreTechnology or Integration · 1 January 2020Scenic Biotech collaborated with Genentech to discover modifier genes to tackle complex diseases. Scenic utilizes its Cell-Seq platform to identify drug targets in multiple therapeutic areas of Genentech's interest. This multi-year partnership highlights mutual commitment to innovation and belief in the transformative potential of genetic research. Announced as Scenic's first major pharma collaboration.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Scenic Biotech competitors and assessment

Company assessment

Direct peers

  • Maze Therapeutics: Pioneer in modifier-gene-driven drug discovery, also founded by Charles Homcy and using functional genomics to identify compensatory genes in genetic disease. Closest conceptual comparator to Scenic's modifier-therapy thesis.
  • Denali Therapeutics: Focused on neurodegeneration and lysosomal biology, with a lead program (tividenofusp alfa) for CLN2/Batten Disease. Directly competes with Scenic's PLA2G15 program in lysosomal indications and shares brain-penetrant therapeutic modality.

Broad incumbents

  • Recursion Pharmaceuticals: AI/ML-enabled drug discovery platform using high-throughput biology for novel target identification. Competes with Cell-Seq in supplying pharma partners with functional-genomics-derived targets, though at a much larger scale.
  • BridgeBio Pharma: Genetic-disease-focused biotech with multiple rare-disease programs including in cardiology and metabolism. Comparable as a rare-disease therapeutics platform that licenses and develops genetically validated targets.
  • BioMarin Pharmaceutical: Established rare-disease biotech with marketed therapies in Batten Disease (Brineura) and other lysosomal disorders. Direct overlap with Scenic's PLA2G15 indications and represents both competitor and potential out-licensing partner.

Emerging players

  • Crinetics Pharmaceuticals: Rare-endocrine-disease biotech with approved therapy (Palsonify). Comparable as a development-stage rare-disease company using genetic/biological insights to develop small-molecule therapies with pharma-partnered economics.
  • Insitro: ML-enabled functional-genomics platform identifying novel targets through induced pluripotent stem cells. Competes with Cell-Seq in supplying pharma partners with genetically validated targets, with a partnership model overlapping with Scenic's.
  • Verve Therapeutics: Genetic-medicine company using genomics-derived insights to develop cardiovascular therapies, with pharma partnerships (e.g., Lilly). Comparable as a platform company monetizing genetic insights through partnerships and in-house pipeline.

Others

  • Haplogen Genomics: Co-founded by Scenic co-founder Sebastian Nijman; uses haploid genetic screens for target discovery. Closely related platform technology peer founded on the same scientific foundation as Cell-Seq.

Regional players

  • MaaT Pharma: European clinical-stage biotech focused on microbiome-related therapies for severe diseases. Comparable as a European rare-disease biotech in similar development stage and partnership model, though different therapeutic modality.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Scenic Biotech social profiles

Digital presence

Scenic Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Scenic Biotech leadership team

Management profile

Number of profiles

Profiles15 records

Scenic Biotech funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Scenic Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scenic Biotech

What does Scenic Biotech do?

Scenic Biotech develops disease-modifying therapies for rare neuro- and metabolic diseases using its proprietary Cell-Seq™ functional genomics platform, which systematically identifies modifier genes—compensatory genes that counteract disease-causing mutations—via haploid human cell screening and gene-trap mutagenesis. The company licenses this platform to major pharmaceutical companies (Genentech, Bristol Myers Squibb, Alnylam, Ono Pharmaceutical) for target discovery while independently developing a pipeline of first-in-class small molecule and ASO therapeutics, including lead candidate SC6177 (a brain-penetrant PLA2G15 inhibitor for neurodegenerative lysosomal diseases).

Is Scenic Biotech a public or private company?

Scenic Biotech is a private company. It is classified as venture growth investor backed and is currently operating.

When was Scenic Biotech founded?

Scenic Biotech was founded in 2017. It employs 11 to 50 people.

Where is Scenic Biotech based?

Scenic Biotech is headquartered in Amsterdam, Netherlands, in the Europe region.

How does Scenic Biotech make money?

Three revenue lines are on record. Platform Licensing & Collaborations are the primary driver. The others are in-house Therapeutic Development and series A Funding.

Who are Scenic Biotech's main competitors?

Direct peers on record are Maze Therapeutics and Denali Therapeutics. Broad incumbents are Recursion Pharmaceuticals, BridgeBio Pharma and BioMarin Pharmaceutical. Emerging players are Crinetics Pharmaceuticals, Insitro and Verve Therapeutics. Haplogen Genomics is listed as an others. MaaT Pharma is listed as a regional player.

Does Scenic Biotech have an API?

No public API is recorded for Scenic Biotech.

What industry is Scenic Biotech in?

Scenic Biotech's product category is Rare Disease Therapeutics. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterThe path to the clinic: how Scenic Biotech is advancing lysosomal biology toward 2027Scenic Biotech is preparing to enter clinical development of its lead program SC6177 in early 2027. The brain-penetrant small molecule targets PLA2G15 for lysosomal storage diseases and neurodegenerative conditions. The company plans to file at least one more IND within 24 months.The Pharma LetterNeurology veteran Judith Walker named Scenic CMOScenic Biotech appointed Judith Walker as chief medical officer, bringing over 25 years in neurological drug development. The company plans to move its lead program, SC6177, into first-in-human trials in early 2027. Walker previously served as CMO at ARTHEx Biotech and Cerecin.BioSpaceScenic Biotech Appoints Renowned Neurology Drug Development Leader Dr. Judith Walker as Chief Medical OfficerScenic Biotech appointed Dr. Judith Walker as Chief Medical Officer to lead its transition into clinical development. The company's lead program SC6177, targeting lysosomal dysfunction, is advancing toward first-in-human trials in early 2027. Walker brings over 25 years of neurology drug development experience.GlobeNewswireScenic Biotech Joins Michael J. Fox Foundation’s LITE Program to Explore New Disease-Modifying Approach for Parkinson's DiseaseScenic Biotech announced it has joined the Michael J. Fox Foundation's LRRK2 Investigative Therapeutics Exchange (LITE) program to evaluate its first-in-class PLA2G15 inhibitor program as a disease-modifying approach for Parkinson's disease, including patients with LRRK2 mutations. The collaboration will leverage LITE's LRRK2 biology expertise, biomarker infrastructure, and validated preclinical models developed at the University of Dundee to generate translational data supporting future clinical development. Scenic's PLA2G15 inhibitors are designed to elevate endogenous BMP levels and restore lysosomal function, a core driver of neurodegeneration linked to impaired glucocerebrosidase activity in genetic forms of Parkinson's disease.European BiotechnologyScenic Biotech joins Michael J. Fox LRRK2 consortium with a novel lysosomal bet on Parkinson’sScenic Biotech joined the Michael J. Fox Foundation's LRRK2 consortium to test a Parkinson's approach targeting PLA2G15, not LRRK2 or GCase directly. The company plans to file an IND by year-end and enter the clinic in 2027, following recent phase 2b failures of LRRK2 and GCase candidates.The Pharma LetterScene set for Scenic to take ‘top-notch science’ into the clinicScenic Biotech is advancing its lead inhibitor SC6177 for PLA2G15, targeting neurodegenerative diseases by restoring lysosomal function. The company has collaborations with four pharma partners and expects to enter clinical trials this year. It plans to raise additional funding to support its clinical plan.GlobeNewswireScenic Biotech Enters License and Research Agreement with Ono PharmaceuticalScenic Biotech announced a license and research agreement with Ono Pharmaceutical to use its Cell-Seq platform for discovering novel therapeutic targets. This marks Scenic's fourth Cell-Seq collaboration with a major pharmaceutical company, joining ongoing agreements with Genentech, Bristol Myers Squibb, and Alnylam.GlobeNewswireScenic Biotech Appoints Dr. Roland W. Bürli as CSO to Advance Pipeline of Modifier Therapies in Neuro- and Metabolic DiseasesScenic Biotech appointed Dr. Roland W. Bürli as Chief Scientific Officer, effective September 1, 2025. He brings over 25 years of drug development experience and will lead the company's pipeline of modifier therapies for neurodegenerative and metabolic diseases. The appointment aims to accelerate the lead program toward clinical evaluation.GlobeNewswireScenic Biotech Publishes Novel Drug Target for Mitochondrial and Cardiac Disease in NatureScenic Biotech published a Nature study identifying ABHD18 as a modifier gene for Barth Syndrome, a cardiolipin metabolism disorder. Loss of ABHD18 rescued mitochondrial defects and suppressed disease hallmarks in preclinical models. The company says this validates its Cell-Seq platform for discovering disease-modifying genes.GlobeNewswireScenic Enters License and Research Agreement with AlnylamScenic Biotech announced a license and research agreement with Alnylam Pharmaceuticals to use its Cell-Seq platform for discovering novel targets for RNAi therapeutics. The collaboration is Scenic's third Cell-Seq partnership with a major US biotech or pharma, following agreements with Genentech and Bristol Myers Squibb.